Prostate specific membrane antigen (PSMA) ligands and uses thereof

The present disclosure relates to prostate specific membrane antigen (PSMA) ligands. In particular, the disclosure relates to PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal. The disclosure also relates to the use of these compounds in im...

Full description

Saved in:
Bibliographic Details
Main Authors FUGAZZA, LORENZA, RAY, SANGEETA, CHICCO, DANIELA, POMPER, MARTIN GILBERT, MARIANI, MAURIZIO F
Format Patent
LanguageChinese
English
Published 16.04.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure relates to prostate specific membrane antigen (PSMA) ligands. In particular, the disclosure relates to PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal. The disclosure also relates to the use of these compounds in imaging and in the treatment of prostate cancer.
Bibliography:Application Number: TW20209122386